The ninth edition of the Istanbul Fashion Connection (IFCO) is poised to gather an estimated 30,000 trade visitors and 400 exhibitors this February, highlighting Turkey's expanding influence in the global apparel sourcing landscape.
Adidas unveils its first U.S.-exclusive soccer flagship at the American Dream Mall, launching an immersive retail experience and exclusive product lines as anticipation builds for the 2026 FIFA World Cup hosted in North America.
Life sciences and diagnostics firm Revvity (RVTY) closed 2025 with results surpassing internal targets, driven by robust diagnostics performance. While management provided initial 2026 guidance, it remains conservative, banking on market stabilization rather than a broad recovery.
Aptiv capped off 2025 with record fourth-quarter sales and detailed a transformative 2026 outlook, headlined by the imminent spin-off of its Electrical Distribution Systems unit into VersaGen. The automotive tech leader is navigating currency headwinds and strategic investments to expand beyond traditional auto markets.
IDEXX Laboratories (IDXX) reported robust double-digit growth for Q4 2025, driven by record placements of its premium diagnostic instruments and expanding test utilization. While acknowledging persistent softness in U.S. veterinary visit volumes, the company outlined a confident initial 2026 forecast, banking on its innovation pipeline and the transformative impact of its inVue Dx system.
Amazon will discontinue its Amazon One palm-scanning payment and entry technology at retail locations in 2026, marking a retreat from one of its most ambitious physical commerce experiments.
As the 2026 Winter Olympics approach, the event is set to be the final one governed by a fragmented system of regulations for transgender athletes' participation. With the IOC poised to introduce universal guidelines, the Games in Italy spotlight a global debate balancing inclusion, fairness, and the future of women's sport.
With the 2025 tax filing season now open, millions of Americans are looking ahead to their 2026 refunds. We break down how to track your payment, expected wait times, and the potential impact of recent legislation on your bottom line.
After months of political gridlock and a series of no-confidence votes, France's parliament is poised to adopt the contentious 2026 budget. The survival of Prime Minister Sebastien Lecornu's government hinges on Monday's vote, marking a critical juncture for the nation's fiscal and political stability.
Meta Platforms' relentless investment in artificial intelligence infrastructure is set to drive capital expenditures to unprecedented levels in 2026, raising questions about long-term returns for the cash-rich tech giant.
As the Federal Reserve prepares for a potential policy shift in 2026, analysts flag real estate, financials, energy, and consumer discretionary as vulnerable sectors. Structural challenges and changing macroeconomic conditions could pressure performance despite broader market gains.
With the FIFA World Cup in North America, the Milano Cortina Winter Olympics, and a packed calendar of major events, 2026 is poised to be a landmark year for sports. Brands and retailers are deploying sophisticated strategies that prioritize cultural marketing and community engagement over mere sales spikes, navigating a landscape where consumer loyalty is won through storytelling, not just sponsorship.
Despite recent guidance revisions, Mobileye Global retains strong buy ratings from analysts who see significant upside potential, as the company positions 2026 for a strategic transition in the autonomous driving sector.
Following a price target adjustment by Leerink Partners, Kura Oncology (KURA) is drawing investor focus to its 2026 clinical milestones and commercial strategy for its newly launched AML drug, ziftomenib.
Analysts at Stifel have raised their price target for Nurix Therapeutics (NRIX) to $35, maintaining a Buy rating ahead of anticipated 2026 clinical milestones for its lead asset, bexobrutinib. The move comes as Wells Fargo also adjusted its target, highlighting divergent near-term views but shared long-term optimism for the biotech firm.
Twist Bioscience kicks off fiscal 2026 with robust growth, reporting a 17% year-over-year revenue increase to $103.7 million. The company credits its semiconductor-based DNA synthesis platform and surging demand from AI-enabled drug discovery programs as key drivers, while reiterating its path to adjusted EBITDA breakeven within the year.
After a punishing multi-year slump, materials stocks are showing signs of life in 2026. Dow and LyondellBasell, offering yields of 5% and 10.9% respectively, present a high-risk, high-reward proposition for income investors betting on a sector recovery.
After a protracted political standoff, France's long-delayed 2026 budget is set for adoption, granting Prime Minister Sebastien Lecornu a hard-won victory but leaving President Macron's domestic reform agenda in limbo ahead of the 2027 election.
While carrier capacity and reliability show signs of recovery, a new FreightWaves white paper reveals a more complex and unforgiving cost environment emerging for 2026. Shippers must navigate a labyrinth of rules, fees, and contract nuances that are quietly driving up expenses.
The latest collaborative industry analysis from FreightWaves and Ryder details shifting dynamics in trucking, maritime, and intermodal sectors, offering a data-driven forecast for the pivotal first quarter of 2026.
